ArticleThe Analyst2023
Evaluating nanoparticle localisation in glioblastoma multicellular tumour spheroids by surface enhanced Raman scattering.
Article in The Analyst, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 12 citations in OpenAlex.
- Development of a surface enhanced Raman scattering lateral flow immunoassay with prolonged reproducibility and stability over time.The Analyst · 2026Article
- Nanoparticles for Glioblastoma Treatment.Pharmaceutics · 2025Review
- Mass Spectrometry-Based Applications of Spheroids in Cancer Biology.Annual review of analytical chemistry (Palo Alto, Calif.) · 2025Review
- Review
- Chemotherapeutic Drug Delivery Nanoplatform Development: From Physicochemical to Preclinical Evaluation.International journal of molecular sciences · 2024Article
- Advancing SERS as a quantitative technique: challenges, considerations, and correlative approaches to aid validation.Nano convergence · 2024Review
- Review
- SERS in 3D cell models: a powerful tool in cancer research.Chemical Society reviews · 2024Review
- Bridging pandemic and oncology challenges: Surface-enhanced Raman spectroscopy in the fight against COVID-19 and cancer.Science progressReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Glioblastoma multiforme (GBM) is a particularly aggressive and high-grade brain cancer, with poor prognosis and life expectancy, in urgent need of novel therapies. These severe outcomes are compounded by the difficulty in distinguishing between cancerous and non-cancerous tissues using conventional imaging techniques. Metallic nanoparticles (NPs) are advantageous due to their diverse optical and physical properties, such as their targeting and imaging potential. In this work, the uptake, distribution, and location of silica coated gold nanoparticles (AuNP-SHINs) within multicellular tumour spheroids (MTS) derived from U87-MG glioblastoma cells was investigated by surface enhanced Raman scattering (SERS) optical mapping. MTS are three-dimensional
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.